146 related articles for article (PubMed ID: 34293786)
1. Tocilizumab for the Management of Thyroid-Associated Orbitopathy.
Smith LD; Moscato EE; Seiff SR
Ophthalmic Plast Reconstr Surg; 2022 Mar-Apr 01; 38(2):188-192. PubMed ID: 34293786
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican population.
Ceballos-Macías José J; Rivera-Moscoso R; Flores-Real Jorge A; Vargas-Sánchez J; Ortega-Gutiérrez G; Madriz-Prado R; Velasco-Ramos PC; Muñoz-Monroy Omar E; Meneses-Pérez Anna C; Fernández-Morales Irma N; Hernández-Moreno A
Ann Endocrinol (Paris); 2020 Jun; 81(2-3):78-82. PubMed ID: 32340849
[TBL] [Abstract][Full Text] [Related]
3. Response to tocilizumab treatment in Graves' ophthalmopathy by measuring rectus muscle thickness and chemosis using optical coherence tomography.
de-Pablo-Gómez-de-Liaño L; Fernández-Vigo JI; Troyano-Rivas J; Niño-Rueda C; Romo-López Á; Gómez-de-Liaño R
Arch Soc Esp Oftalmol (Engl Ed); 2018 Aug; 93(8):386-391. PubMed ID: 29937157
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial.
Perez-Moreiras JV; Gomez-Reino JJ; Maneiro JR; Perez-Pampin E; Romo Lopez A; Rodríguez Alvarez FM; Castillo Laguarta JM; Del Estad Cabello A; Gessa Sorroche M; España Gregori E; Sales-Sanz M;
Am J Ophthalmol; 2018 Nov; 195():181-190. PubMed ID: 30081019
[TBL] [Abstract][Full Text] [Related]
5. Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab.
Canas CA; Bonilla-Abadia F; Vallejo K; Rengifo HM; Gallon MA; Tobon GJ
Endocr Metab Immune Disord Drug Targets; 2018; 18(6):665-667. PubMed ID: 29962351
[TBL] [Abstract][Full Text] [Related]
6. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
7. Predicting the Development of Orbitopathy in Graves Thyroidopathy Patients: The Potential Role of TSI Testing.
Takakura A; Kirkeby K; Earle K; Silkiss RZ
Ophthalmic Plast Reconstr Surg; 2015; 31(5):369-72. PubMed ID: 25585304
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab versus Rituximab in Patients with Moderate to Severe Steroid-resistant Graves' Orbitopathy.
Bennedjaï A; Bouheraoua N; Gatfossé M; Dupasquier-Fediaevsky L; Errera MH; Tazartes M; Borderie V; Hennocq Q; Dellal A; Riviere S; Heron E; Fain O; Mekinian A
Ocul Immunol Inflamm; 2022 Feb; 30(2):500-505. PubMed ID: 32965148
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves' Ophthalmopathy, a Report of Three Cases.
Maldiney T; Deschasse C; Bielefeld P
Ocul Immunol Inflamm; 2020; 28(2):281-284. PubMed ID: 30457413
[No Abstract] [Full Text] [Related]
10. Treatment of active corticosteroid-resistant graves' orbitopathy.
Pérez-Moreiras JV; Alvarez-López A; Gómez EC
Ophthalmic Plast Reconstr Surg; 2014; 30(2):162-7. PubMed ID: 24503568
[TBL] [Abstract][Full Text] [Related]
11. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
[TBL] [Abstract][Full Text] [Related]
12. Treatment of corticosteroid-resistant Graves' orbitopathy with tocilizumab: a single-centre prospective study.
Dorado Cortez O; Grivet D; Perrillat N; Gain P; Thuret G
Orbit; 2023 Aug; 42(4):411-417. PubMed ID: 36065465
[TBL] [Abstract][Full Text] [Related]
13. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal correlation of thyroid-stimulating immunoglobulin with clinical activity of disease in thyroid-associated orbitopathy.
Dragan LR; Seiff SR; Lee DC
Ophthalmic Plast Reconstr Surg; 2006; 22(1):13-9. PubMed ID: 16418659
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves' orbitopathy: an observational study.
Boutzios G; Chatzi S; Goules AV; Mina A; Charonis GC; Vlachoyiannopoulos PG; Tzioufas AG
Front Endocrinol (Lausanne); 2023; 14():1186105. PubMed ID: 37424868
[TBL] [Abstract][Full Text] [Related]
16. Cytokine production in thyroid eye disease: in vitro effects of dexamethasone and IL-6 blockade with tocilizumab.
Leszczynska A; Molins B; Fernández E; Adán A; Ortiz-Perez S
Graefes Arch Clin Exp Ophthalmol; 2019 Oct; 257(10):2307-2314. PubMed ID: 31338585
[TBL] [Abstract][Full Text] [Related]
17. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
Woo YJ; Jang SY; Lim TH; Yoon JS
Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes in corticosteroid-refractory Graves' orbitopathy treated with tocilizumab.
Moi L; Hamedani M; Ribi C
Clin Endocrinol (Oxf); 2022 Sep; 97(3):363-370. PubMed ID: 34908176
[TBL] [Abstract][Full Text] [Related]
19. Role of methotrexate in thyroid-related orbitopathy.
Rubinov A; Zommer H; Aghazadeh H; Weis E
Can J Ophthalmol; 2018 Feb; 53(1):34-38. PubMed ID: 29426438
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves' orbitopathy.
Park J; Kim J; Kim SS; Choi HY
Front Endocrinol (Lausanne); 2023; 14():1153312. PubMed ID: 37223049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]